10-Q: Kyverna Therapeutics Reports Q1 2025 Financial Results, Highlights Clinical Progress

Kyverna Therapeutics reports a net loss of $44.6 million for Q1 2025, focusing on advancing its lead product candidate, KYV-101, through clinical trials.

Summary

• Kyverna Therapeutics, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2025.
• The company reported a net loss of $44.6 million for the three months ended March 31, 2025, compared to a net loss of $26.7 million for the same period in 2024.
• Research and development expenses increased to $37.4 million, driven by investments in the KYV-101 program and CMC readiness.
• General and administrative expenses also increased to $9.975 million.
• As of March 31, 2025, Kyverna had cash, cash equivalents, and available-for-sale marketable securities totaling $242.6 million.
• Management believes these funds will be sufficient to fund operations for at least the next 12 months.
• The company is focused on advancing KYV-101 through late-stage clinical development for autoimmune diseases.
• Kyverna expects to file a BLA for KYV-101 in stiff person syndrome (SPS) in 2026.
• The company is also progressing clinical trials in myasthenia gravis (MG) and lupus nephritis (LN).
• Kyverna filed a shelf registration statement on Form S-3, covering the offer and sale of up to $250.0 million in securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is operating at a loss, it has a strong cash position and is making significant progress in clinical development. The RMAT designations and alignment with the FDA are positive indicators, but the material weaknesses in internal control and the shareholder lawsuit are concerning.

Positives

• Kyverna has a strong cash position of $242.6 million, expected to fund operations for at least 12 months.
• The company is making significant progress in clinical development, particularly with KYV-101.
• KYV-101 has received RMAT designations from the FDA for both SPS and MG, potentially accelerating the approval process.
• Enrollment is complete in the pivotal Phase 2 trial for SPS.
• The company has aligned with the FDA on a registrational Phase 2 trial design in SPS.
• The company has supplied clinical product from two clinical manufacturing sites for which the FDA accepted comparability data between manufacturing sites in April 2025.

Negatives

• Kyverna is currently operating at a loss, with a net loss of $44.6 million for Q1 2025.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is involved in a shareholder class action lawsuit alleging material misstatements or omissions in the IPO registration statement.
• The FDA is investigating a serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies, such as KYV-101.

Risks

• The company's success depends heavily on the success of its product candidates, particularly KYV-101.
• Clinical trials may be delayed or unsuccessful.
• The company faces competition from other pharmaceutical and biotechnology companies.
• Use of product candidates could be associated with side effects or safety risks.
• The company relies on third parties for manufacturing and clinical trials.
• The company depends on intellectual property licensed from third parties.
• The regulatory approval processes are lengthy and unpredictable.
• The company may be unable to obtain or maintain necessary rights to develop current and any future product candidates on acceptable terms.
• The company may be subject to securities litigation, which is expensive and could divert management attention.
• Unfavorable global economic conditions, including any adverse macroeconomic conditions or geopolitical events could adversely affect our business, financial condition, results of operations or liquidity, either directly or through adverse impacts on certain of the third parties on which we rely to conduct certain aspects of our preclinical studies or clinical trials.

Future Outlook

Based on its current operating plan, management estimates that its existing cash and cash equivalents and available-for-sale marketable securities balances will be sufficient to fund its operating plan and capital expenditure requirements for at least the next 12 months from the filing date of this Quarterly Report on Form 10-Q. The company anticipates filing a BLA for KYV-101 in SPS in 2026.

Management Comments

• Management estimates that its existing cash and cash equivalents and available-for-sale marketable securities balances will be sufficient to fund its operating plan and capital expenditure requirements for at least the next 12 months from the filing date of this Quarterly Report on Form 10-Q.
• The company plans to monitor expenses and raise additional capital through equity or debt financings, strategic alliances or licensing arrangements.

Industry Context

Kyverna is operating in the competitive biopharmaceutical industry, specifically focused on cell therapies for autoimmune diseases. The company faces competition from established pharmaceutical companies and other biotechnology firms developing treatments for similar indications. The company's approach aims for deep B cell depletion, an immune reset, and long-term remission in autoimmune diseases, which may present a significant advantage over current standard-of-care therapies.

Comparison to Industry Standards

• Kyverna's KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation.
• The same underlying CAR in KYV-101 has completed a 20-patient Phase 1 trial in oncology conducted by the NIH, and the results from this Phase 1 trial published in Nature Medicine reported similar rates of durable antitumor responses while delivering improved tolerability in the clinic among adult oncology patients, as compared to the CAR used to create Yescarta.
• The company's focused clinical development pipeline includes a pivotal Phase 2 trial of KYV-101 in stiff person syndrome, or SPS, a Phase 2 trial of KYV-101 in myasthenia gravis, or MG, and two multi-center Phase 1/2 trials for patients with lupus nephritis, or LN.

Legal Proceedings

• A shareholder class action complaint was filed in the United States District Court for the Northern District of California against the Company, certain of its current and former officers and directors, and the underwriters of the IPO.
• The amended complaint alleges that the registration statement on Form S-1 filed in connection with the IPO and the prospectus contained therein contained material misstatements or omissions in violation of federal securities laws.

Related Party Transactions

• For the three months ended March 31, 2024, the Company recorded less than $ 0.1 million to deferred offering costs related to an advisory services agreement with one of its board members.
• On January 12, 2024, the Company and the Former CEO entered into a note forgiveness letter, pursuant to which the promissory note and all accrued interest thereon in an aggregate amount of $ 1.1 million were forgiven.
• The Company had $ 0.6 million and $ 0.4 million in other accrued expenses and current liabilities on the condensed balance sheet as of March 31, 2025 and December 31, 2024, respectively, related to severance payments for the Former CEO.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will impact shareholder value.
• Employees: The company's growth and development plans will affect employment opportunities and job security.
• Patients: The company's success in developing and commercializing new therapies will impact treatment options for autoimmune diseases.
• Suppliers and Creditors: The company's financial stability will affect its ability to meet its obligations to suppliers and creditors.

Next Steps

• Continue advancing KYV-101 through clinical trials.
• File a BLA for KYV-101 in SPS in 2026.
• Report interim data from the initial six-patient Phase 2 cohort in MG in the second half of 2025.
• Report Phase 1 data from the two Phase 1/2 trials in LN in the second half of 2025.
• Identify next priority indications to advance into late-stage development.

Key Dates

Keywords

KYV-101, clinical trials, autoimmune diseases, cell therapy, financial results, RMAT designation, stiff person syndrome, myasthenia gravis, lupus nephritis, biopharmaceutical